CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
Ibudilast +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03594435
NCT03594435Phase 2Completed
CompareCT.gov

A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder

University of California, Los Angeles·interventional·Posted Jul 20, 2018·Updated Nov 27, 2024

In Brief

A Phase 2 clinical trial evaluating Ibudilast and Placebo oral capsule for Alcohol Use Disorder. Completed, enrolled 102 participants across 1 site.

Detailed Summary

This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA), MediciNova

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 20, 2018
Enrollment StartOct 1, 2018
Primary CompletionApr 19, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.0 years ago

Interventions

Ibudilastdrug

targets neurotrophin signaling and neuroimmune function

Placebo oral capsuledrug

matched to active drug, ibudilast